On the basis of these results, a clinical translation of 177Lu-AMTG is highly recommended to assess a potential improved therapeutic value for radioligand therapy of GRPR-expressing malignancies, such as prostate and breast cancer. This evidence concerns the gene GRPR and breast carcinoma.